What are the common side effects of Asiminib/Aximinib?

Asciminib is a new type of BCR-ABL1 inhibitor. As the first STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, it has shown a unique targeting mechanism and side effect profile in clinical applications. Although it is better tolerated than traditional TKI drugs such as imatinib or nilotinib in some aspects, it is still necessary to pay attention to the adverse reactions it may cause during clinical use.

Judging from global post-marketing data, common side effects of asinib mainly include gastrointestinal reactions (such as nausea, vomiting, diarrhea), fatigue, headache, rash and musculoskeletal pain. In addition, hemogram abnormalities may appear in laboratory tests, including leukopenia, neutropenia, and thrombocytopenia, indicating that it still carries a certain risk in terms of bone marrow suppression. Individual patients may experience elevated liver function indicators, such as mild abnormalities in ALT and AST. This is usually reversible but requires monitoring.

Among the more serious adverse reactions, rare occurrences of elevated pancreatic enzymes, pancreatitis, QT interval prolongation or arrhythmia have also been reported. Therefore, clinicians should conduct a comprehensive assessment based on the patient's underlying heart disease history and other risk factors when prescribing Asinib, and regularly monitor electrocardiogram and electrolyte levels during medication.

In addition, because asinib is a drug metabolized by CYP3A4, there are potential interactions between it and other drugs. For example, combined use with CYP3A4 inhibitors or inducers may affect blood drug concentrations, resulting in weakened efficacy or increased toxicity. Combination regimens should be carefully chosen especially in multidrug regimens.

In general, although asinib is superior to traditional TKIs in terms of target specificity and side effect control,TKIs, when used as first-line or after drug resistance, individualized assessment of risks and benefits is still required, and rational use of drugs based on standardized monitoring.

Reference materials:https://www.novartis.com/our-products/pipeline/asciminib